RA
LGND icon

RiverPark Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

RiverPark Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432K Buy
1,368
+709
+108% +$167K 0.2% 65
2026
Q1 		$132K Buy
+659
New +$130K 0.05% 104

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RiverPark Advisors's LGND Position: Q2 2026 in Review

RiverPark Advisors increased its Ligand Pharmaceuticals (LGND) stake by 108% in Q2 2026, buying an estimated $167K and bringing the position to 1,368 shares worth $432K. The position accounts for 0.2% of the portfolio, ranked #65.

RiverPark Advisors first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • RiverPark Advisors held 1,368 shares of Ligand Pharmaceuticals worth $432K as of Q2 2026.
  • RiverPark Advisors bought 709 Ligand Pharmaceuticals shares in Q2 2026, an estimated $167K.
  • Ligand Pharmaceuticals made up 0.2% of RiverPark Advisors's portfolio in Q2 2026, its #65 holding.
  • RiverPark Advisors first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on RiverPark Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.